Background: A debate exists about whether interleukin 10 (IL-10) polymorphisms (IL-10−1082G/A and IL-10−592C/A) confer additional risk for cervical cancer. To derive a more precise estimation of the relationship between IL-10 polymorphisms and cervical cancer risk, we conducted a meta-analysis of all available studies relating the −1082G/A and −592C/A polymorphisms of the IL-10 gene to the risk of developing cervical cancer.
Methods: Eight studies were eligible for IL-10 −1082G/A (1498 cases and 1608 controls), and 5 studies were eligible for IL-10 −592C/A (2396 cases and 1388 controls). Pooled odds ratios (ORs) were appropriately derived from fixed-effects or random-effects models. Subgroup analyses were performed by ethnicity and Hardy-Weinberg equilibrium in the controls.
Results: In the overall analysis, no significant association between the IL-10−1082G/A polymorphism and the risk of cervical cancer was observed. In the subgroup analysis by ethnicity, IL-10 −1082A allele was associated with decreased cervical cancer susceptibility among whites (A vs G: OR, 0.39; 95% confidence interval [CI], 0.32–0.47). Studies with controls deviated from Hardy-Weinberg equilibrium showed an evident association in dominant model (GA/AA vs GG: OR, 1.73 [95% CI, 1.04–2.89]). On the other hand, with respect to −592C/A polymorphism, significantly elevated cervical cancer risk was found in the overall analysis (A vs C: OR, 1.16 [95% CI, 1.04–1.31]; AA vs CC: OR, 1.36 [95% CI, 1.00–1.84]; CA/AA vs CC: OR, 1.18 [95% CI, 1.01–1.39]; AA vs CC/CA: OR, 1.25 [95% CI, 1.01–1.55]). Stratified analysis indicated that significantly increased risks were also found among Asians in the allelic model (A vs C: OR, 1.23 [95% CI, 1.01–1.49]).
Conclusions: Interleukin 10−1082 G/A polymorphism showed no effect on cervical cancer risk in the overall analysis. The genetic polymorphism in IL-10−592C/A is a risk factor for developing cervical cancer, especially for Asians.
*Department of Gynecologic Oncology, Jiangsu Cancer Hospital and Research Institute; †Department of Molecular Cell Biology and Toxicology, School of Public Health, Nanjing Medical University; and ‡Department of Gynaecology and Obstetrics, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing, China.
Address correspondence and reprint requests to Qiang Wu, PhD, Department of Gynecologic Oncology, Jiangsu Cancer Hospital and Research Institute, 42 Baiziting, Nanjing 210009, China. E-mail: firstname.lastname@example.org.
The study was supported by grant from the Jiangsu Provincial Department of Sciences and Technology (BS2006072).
Drs Ni and Ye contributed equally to this work.
The authors declare no conflicts of interest.
Received July 31, 2012
Accepted Sept 15, 2012